User Information

  • The Continuing Education courses offered on this website are not approved for Continuing Medical Education (CME) credit for physicians.

New Hot Topics

Clinical Applications & Imaging Considerations of Gadopiclenol Injection

Clinical Applications & Imaging Considerations of Gadopiclenol Injection

Presented by:
Lawrence N. Tanenbaum, MD, FACR | Applied Radiology

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

In September 2022, Gadopiclenol injection, which is both macrocyclic (stable) and has high relaxivity properties received FDA marketing approval and may provide dosing options that can decrease gadolinium exposure, particularly in vulnerable patients.

In this accredited webinar, the assessment of Gadopiclenol injection in neuro, body, and pediatric MR imaging will be presented by a panel of MR imaging experts and will include commentary from Lawrence N. Tanenbaum, MD. To encourage audience participation, a live Q & A session will follow the discussion.

Radiologic Technologist Radiology Administrator
Development and Use of Elucirem™ (gadopiclenol) Injection, a Macrocyclic, High-relaxivity GBCA for CE-MRI

Development and Use of Elucirem™ (gadopiclenol) Injection, a Macrocyclic, High-relaxivity GBCA for CE-MRI

Published by:
Applied Radiology

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

One technique for reducing Gd exposure is to use a high-relaxivity GBCA that can be used at a lower dose than a conventional GBCA without impact on image quality. Until recently, however, the GBCA with the highest relaxivity was a linear agent. Consequently, it has been widely recognized for some time that it would be preferable if a GBCA was both macrocyclic in structure and high relaxivity, and that such an agent could be used to reduce Gd exposure by decreasing the amount of Gd injected.

A new GBCA that is both macrocyclic and high relaxivity has been developed and received FDA marketing approval in September 2022. A group of radiologists with extensive experience in contrast-enhanced (CE)-MRI convened to discuss this new GBCA, Elucirem™ (gadopiclenol) injection, and this monograph presents a summary of this expert panel forum.

Radiologic Technologist Radiology Administrator

What's New

Managing Patients Undergoing MRI with Gadolinium Contrast Media

Managing Patients Undergoing MRI with Gadolinium Contrast Media

Presented by:
Donna Roberts, MD, MS

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

Radiologic Technologist Radiology Administrator

 

Opportunities Beyond R.T. | Career Pathway Enhancement

MRI Contrast Agents and Relaxivity: The Physics Behind the Injection

Presented by:
Jeffrey H Maki, MD, PhD

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

Radiologic Technologist Radiology Administrator

Hot Topics

Contrast Safety

Contrast Safety

Presented by:
Vanessa L. Williams, MD

Published by:
Creative Training Solutions, Inc.

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

Radiologic Technologist Radiology Administrator

 

Radiation and Radiology Safety - 2nd Edition

Radiology and Radiation Safety in the Delivery of Patient Care – 2nd Edition

Authored by:
Maggie Aime, BSN, RN

Published by:
Creative Training Solutions, Inc.

Accredited by The Association for Medical Imaging Management (AHRA) for 4.0 Category “A” ARRT and CRA credits and MedEd America for 4.0 ANCC Nursing CEU's.

Radiologic Technologist Radiology AdministratorNurse

Important User Information: If you are licensed in Vermont, you are not eligible to participate in this Continuing Education program.